Synagis injection: reconstitution no longer required

Synagis (palivizumab), AbbVie's respiratory syncytial virus (RSV) prophylactic for use in high-risk infants and children under two years, has been reformulated and is now available as a solution for injection.

Further information
View Synagis drug record
Summary of Product Characteristics
Manufacturer: AbbVie

The licensed indications, dosing, contraindications and warnings for use, and safety profile for the solution are identical to that of the lyophilised powder formulation which has now been discontinued.

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.